“We believe hospitals that are designated stroke centers, major heart care centers and oncology centers, or those that simply have very active emergency departments should receive special consideration from GE as it chooses how to distribute the product it has available,” AHA wrote.
The shortage of contrast media, an iodine solution injected into patients before CT scans and other imaging tests, stems from strict COVID-19 lockdowns in Shanghai, where GE Healthcare makes the ingredient. GE said the factory was operating at 25 percent capacity last week and plans to resume normal production levels by the end of June.
In its letter, the hospital association urged GE to clarify how hospital allocations of the contrast medium, Omnipaque, will be managed and when hospitals can expect those allotments to increase as production ramps up.
Hospitals will need to conserve current contrast media supplies as GE gradually increases manufacturing capacity. The association said the company should partner with the FDA to issue national guidance on how to extend these supplies. The association also asked how GE plans to meet potential increased demand for contrast media as hospitals resume delayed services after production returns to full capacity.
View the full letter here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.